Trileptal Off-Label Promotion Subject Of Philadelphia U.S. Attorney Subpoena
This article was originally published in The Pink Sheet Daily
Anti-epileptic understood to be subject of civil and criminal investigation into Novartis’ marketing practices. Trileptal subpoena is pursuant to HIPAA privacy provisions of 2003, company says.
You may also be interested in...
Federal prosecutors are likely to bring suits against pharmaceutical manufacturers alleging violations of patient privacy provisions under the Health Insurance Portability & Accountability Act, Assistant U.S. Attorney Michael Loucks said June 22 at an IIR conference in Boston
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.